Molecular-cytogenetic criteria of prognosis of plasma cell myeloma course

Authors

  • Ж. А. Мішаріна Bogomolets National Medical University
  • Ж. М. Мінченко State institution "National Scientific Center for Radiation Medicine of the National Academy of Medical Sciences of Ukraine"
  • А. І. Курченко Bogomolets National Medical University
  • Т. Ф. Любарець State institution "National Scientific Center for Radiation Medicine of the National Academy of Medical Sciences of Ukraine"
  • О. О. Дмитренко State institution "National Scientific Center for Radiation Medicine of the National Academy of Medical Sciences of Ukraine"
  • В. Г. Бебешко State institution "National Scientific Center for Radiation Medicine of the National Academy of Medical Sciences of Ukraine"

DOI:

https://doi.org/10.18372/2306-6407.2.12163

Keywords:

plasma cell myeloma, M-gradient, Bence-Jones paraprotein, fluorescent in situ hybridization (FISH), cytogenetic abnormalities

Abstract

According to the results of the molecular-cytogenetic examination of patients with plasma cell myeloma (PCM) at different stages of therapy, chromosomal abnormalities were detected in almost 80 % of patients. Changes of chromosomes 3, 8, 11 and 13 were predominant, associated with the hyperdiploid type of chromosomal aberrations in the most of patients. IgH translocation with the involvement of chromosomes 4, 11 and 16 was detected in 15 % of patients. The obtained data indicate a significant association of the revealed chromosomal abnormalities with the risk of primary refractory to therapy and the occurrence of complications (range of Spеаrman coefficient from Ro Spеаrman = 0,33 to Ro Spеаrman = 0,5; p < 0,05), which makes it possible to consider them as prognostic criteria for the PCM course.

Author Biographies

Ж. А. Мішаріна, Bogomolets National Medical University

assistant, Department of Clinical Immunology and Allergology, Department of Medical Genetics, Ph.D.

Ж. М. Мінченко, State institution "National Scientific Center for Radiation Medicine of the National Academy of Medical Sciences of Ukraine"

Head of the laboratory of Immunogenetics, Department of Hematology and Transplantation, Institute of Clinical Radiology, doctor of biological sciences, professor

А. І. Курченко, Bogomolets National Medical University

Head of the Department of Clinical Immunology and Allergology with the Department of Medical Genetics, doctor of medical sciences, professor

Т. Ф. Любарець, State institution "National Scientific Center for Radiation Medicine of the National Academy of Medical Sciences of Ukraine"

Leading researcher at the Department of Radiation Onco-Hematology and Stem Cell Transplantation at the Department of Hematology and Transplantation at the Institute of Clinical Radiology, doctor of medical sciences, senior researcher

О. О. Дмитренко, State institution "National Scientific Center for Radiation Medicine of the National Academy of Medical Sciences of Ukraine"

senior researcher, Laboratory of Immunogenetics, Department of Hematology and Transplantology, Institute of Clinical Radiology, Ph.D.

В. Г. Бебешко, State institution "National Scientific Center for Radiation Medicine of the National Academy of Medical Sciences of Ukraine"

Head of the Department of Hematology and Transplantology, Institute of Clinical Radiology, doctor of medical sciences, professor, corresponding member of the National Academy of Medical Sciences of Ukraine

References

The 2016 revision of the World Health Organization classification of lymphoid neoplasms / H. S. Swerdlow, E. Campo, S. A. Pileri [et al.] // Blood. – 2016. – Vol. 127, No 20. – P. 2375–2390.

Рак в Україні, 2011–2012. Захворюваність, смертність, показники діяльності онкологічної служби // Бюлетень Національного канцер-реєстру України. – No 14. – Київ, 2013. – 120 с.

Ионизирующая радиация и онкогематологические заболевания / Под. ред. В. Ф. Чехуна, Д. Ф. Глузмана. – Киев: ДИА, 2016. – 284 с.

Rajkumar V. S. Multiple myeloma: 2014 Updateondiagnosis, risk-stratification, and management / V. S. Rajkumar // Am. J. Hematol. – 2014. – Vol. 89, No 10 – Р. 999–1009.

Becze E. Cytogenetics helps determine diagnosis and prognosis for multiple myeloma / E. Becze // ONS Connect. – 2012. – Vol. 27, No 12 – Р. 18–9.

Mechanisms and clinical applications of genome instability in multiple myeloma / A. Cagnetta, D. Lovera, R. Grasso, [et al.] // Hindawi Publishing Corporation Bio. Med. Research. International. – Vol. 2015, Article ID 943096, 8 pages http://dx.doi.org/10.1155/2015/943096

Pinkel D. Cytogenetic analysis using quantitative high sensitivity fluorescence hybridization / D. Pinkel, T. Straume, J. Gray // PNAS. – 1995. – Vol. 83. – P. 2934–2938.

Guidance for fluorescence in situ hybridization testing in hematologic disorders / D. Wolff, А. Bagg, L. Cooley [et al.] // J. Mol. Diagn. – 2007. – Vol. 9. – No 2. – Р. 134–143.

Mechanisms and clinical applications of chromosomal in stability in lymphoid malignancy / M. K. Maxwell, O. W. Press, M. S. Horwitz, T. Tidwell // Br. J. Haematol. – 2015. – Vol. 171. – P. 13–28.

Chen L. J. Molecular cytogenetic aberrationsinpatients with Multiple Myeloma studied by interphase fluorescence in situ hybridization / L. J. Chen, J. Y. Li // Exp. Oncol. – 2007. – Vol. 29, No 2. – P. 116–120.

Defining the role of gene deletion TP53 in the diagnosis and prognosis of chronic lymphoproliferative neoplasm susing the method of fluorescence in situ hybridization / J. A. Misharina, V. V. Sitko, A. I. Kurchenko [et al.] // Гематологія і переливання крові: міжвідомчий збірник. – 2014. – Вип. 37. – С. 179–189.

p53 gene deletion detected by fluorescence in situ hybridization is an adverse prognostic factor for patients with multiple myeloma following autologous stem cell transplantation / H. Chang, C. Qi, Qi-Long Yi [et al.] // Blood. – 2005. – Vol. 105, No 1. – P. 358–360.

Tǜrkmen S. High Prevalence of Immunoglobulin Light Chain Gene Aberrations as Revealed by FISH in Multiple Myelomaa nd MGUS / S. Tǜrkmen, A. Binder // Genes, Chromosomes and Cancer. – 2014. – Vol. 53, No 8. – P. 650–656.

Gole L. Modified cIg-FISH protocol for multiple myeloma in routine cytogenetic laboratory practice / L. Gole, A. Lin // Cancer Genetics. – 2014. – Vol. 207. – P. 31–34.

q deletions detected by fluorescence in situ hybridization for diagnosis and prognosis of chronic lymphoproliferative neoplasms / V. V. Sitko, J. A. Misharina, J. M. Minchenko [et al.] // Biopolymers and Cell. – 2015. – Vol. 31, No 3. – P. 218–225.

Bea S. Cyclin D1 transcriptional activation in MCL / S. Bea // Blood. – 2014. – Vol. 123, No 13. – P. 1979–1980.

Gozzetti A. Molecular cytogenetics of multiple myeloma / A. Gozzetti, A. Frasconi, R. Crupi //Austin. J. Cancer. Clin. Res – 2014. – Vol. 1, Issue 4. – 1020. ISSN: 2381–909X www.austinpublishinggroup.com

Діагностична та прогностична значущість хромосомних транслокацій із залученням генів важких ланцюгів IGH у хворих на хронічні лімфопроліферативні новоутворення / Ж. А. Мішаріна, В. В. Сітько, Ж. М. Мінченко [та ін.] // Вісник проблем біології та медицини. – 2015. – Том 1 (124), Вип. 4. – С. 187–191.

Роль транслокації t(4;14) та делецій 13q в діагностиці та прогнозі перебігу злоякісних В-клітинних новоутворень / Ж. А. Мішаріна, В. В. Сітько, Ж. М. Мінченко [та ін.] // Вісник проблем біології та медицини. – 2015. – Том 1 (122), Вип. 3. – С. 157–160.

Downloads

Published

2017-12-21

Issue

No. 2 (2017)

Section

Experimental articles